Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
| Revenue (TTM) | $12.95B |
| Gross Profit (TTM) | $7.10B |
| EBITDA | $5.10B |
| Operating Margin | 35.60% |
| Return on Equity | 20.80% |
| Return on Assets | 10.60% |
| Revenue/Share (TTM) | $51.06 |
| Book Value | $82.47 |
| Price-to-Book | 6.58 |
| Price-to-Sales (TTM) | 10.71 |
| EV/Revenue | 10.63 |
| EV/EBITDA | 27.31 |
| Quarterly Earnings Growth (YoY) | -39.00% |
| Quarterly Revenue Growth (YoY) | 11.80% |
| Shares Outstanding | $253.54M |
| Float | $252.76M |
| % Insiders | 0.21% |
| % Institutions | 97.97% |
Volatility is currently expanding
Vertex Pharmaceuticals' moat in cystic fibrosis remains nearly impregnable. The company's diversification efforts are slowly ramping up, and more is to come.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor Relations, and Manisha Pai, Executive Director, Investor Relations, will participate in a fireside chat at the UBS Global Biopharma Conference on Monday, November 16, 2026, at 9:20 a.m. GMT/4:20 a.m. EST. Susie Lisa and Manisha Pai will also participate in a fireside chat at the Jefferies Global H.
VRTX beats Q3 revenue estimates and raises its 2026 outlook as CF therapies and newer drugs drive growth, but acquisition costs pressure earnings.
CRISPR Therapeutics reports higher-than-expected Q3 sales as Casgevy sales surge, while expanding pediatric approvals and advancing multiple clinical programs.
Vertex misses Q3 earnings estimates but beats revenue expectations, driven by CF drug sales and growth in Casgevy and Journavx, prompting a 2026 sales outlook hike.
Vertex Pharmaceuticals Incorporated ( VRTX ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Susie Lisa - Senior Vice President of Investor Relations Reshma Kewalramani - CEO, President & Director Duncan J. McKechnie - Executive VP & Chief Commercial Officer Charles Wagner - Executive VP, COO & CFO Conference Call Participants Cory Kasimov - Evercore ISI Institutional Equities, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Geoffrey Meacham - Citigroup Inc., Research Division Evan Seigerman - BMO Capital Markets Equity Research Brian Abrahams - RBC Capital Markets, Research Division Michael Yee - UBS Investment Bank, Research Division Tazeen Ahmad - BofA Securities, Research Division Akash Tewari - Jefferies LLC, Research Division Terence Flynn - Morgan Stanley, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Operator Good day, and welcome to the Vertex Pharmaceuticals Third Quarter 2026 Earnings Call.
Vertex Pharmaceuticals NASDAQ: VRTX reported third-quarter 2026 revenue growth of 12% year over year, supported by continued cystic fibrosis franchise growth and contributions from newer products including CASGEVY, JOURNAVX and PALSONIFY.
Alyftrek is replacing Trikafta, and that switch is still growing Vertex's cystic fibrosis franchise. Heavy spending on new launches and the Crinetics deal kept profit from rising with sales.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2026, and raised its full year 2026 revenue guidance. “Vertex delivered excellent third quarter results marked by strong revenue growth across the increasingly diversified portfolio, continued advancement of the R&D pipeline, and the successful close of the Crinetics Pharmaceuticals acquisition,” said Reshma Kewalramani, M.D., Ch.
Amgen currently looks stronger on revenue by generating a consistently larger top line in absolute terms compared to Vertex Pharmaceuticals across every observed quarter. Over roughly the last eight quarters, Amgen demonstrated moderate quarter-over-quarter revenue fluctuations, while Vertex Pharmaceuticals maintained a very steady and gradual upward revenue trend.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VRTX and any ticker you trade — then tracks every position and per-strategy win rate.
